Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intismeran + Pembrolizumab in Resected High-Risk Stage I NSCLC
NCT07513376Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- May 2026
- Primary completion
- Aug 2034
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 20
01
Overview
A Phase 3 trial of intismeran autogene in non-small cell lung cancer (NSCLC), sponsored by Merck & Co.. Started May 2026; status: recruiting.
02
Drugs
intismeran autogene
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07513376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07513376.